BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has been cleared by the FDA to begin a double-blind, placebo-controlled phase 1A clinical trial for Thymosin beta 4 (Tß4) in forty healthy volunteers using an intravenous (IV) route of administration. The purpose of the phase 1A trial is to determine if a single dose of Tß4, administered by the IV route, is safe at various escalating dose levels. Upon an acceptable safety assessment and subsequent FDA clearance, it will be followed by a 1B trial where Tß4 will be administered over multiple IV doses at escalating levels in the same subject population.
